Seres Therapeutics
Seres Therapeutics, Inc. is a US-based pioneer and industry leader dedicated to developing microbiome-based therapeutics. The company’s core mission is to leverage its understanding of the human microbiome to create a new class of medicines, primarily focusing on defined bacterial consortia delivered as oral Live Biotherapeutic Products (LBPs). Seres made history with its flagship product, VOWST (formerly SER-109), which received FDA approval in April 2023 for the prevention of recurrent Clostridioides difficile infection (rCDI)—marking it as the first FDA-approved, orally administered microbiome therapeutic. This breakthrough approval is a critical validation of the therapeutic potential of modulating the gut microbiome. Seres continues to advance its R\&D platform, which is designed to significantly reduce the time required to bring microbiome therapeutics to the clinic. By focusing on creating safe, scalable, and highly characterized microbial drugs, Seres is driving the development of next-generation treatments for infectious, metabolic, and inflammatory diseases, and establishing the commercial pathway for this innovative therapeutic modality. The company maintains strategic manufacturing and commercialization partnerships, including a full commercialization transfer agreement with Nestlé Health Science for VOWST, solidifying its influential position in the therapeutic microbiome market.
Latest Market Research Report on Human Microbiome Download PDF Brochure Now
Ferring Pharmaceuticals
Ferring B.V. is a multinational biopharmaceutical company specializing in areas like reproductive medicine, gastroenterology, maternal health, and urology. Within the human microbiome space, Ferring has become a key player through its strategic engagement in developing and commercializing microbiome-based therapeutics. A significant move was the acquisition of Rebiotix in 2018, an enterprise focused on its Microbiota Restoration Therapy (MRT) platform. This acquisition bolstered Ferring’s portfolio, leading to the development and FDA approval of REBYOTA in November 2022. REBYOTA is a fecal microbiota-based therapeutic administered via enema, indicated for the prevention of recurrent Clostridioides difficile infection (rCDI). This milestone positioned Ferring as a leader in bringing donor-derived, microbiome-based therapies to market. The company complements its internal research and development—including its focus on live biotherapeutic products—with external collaborations, such as those with Intralytix and PharmaBiome, to explore bacteriophage-based therapies and novel microbial consortia. Through its global R\&D and manufacturing operations, Ferring is committed to advancing clinically proven microbiome programs and translating cutting-edge science into accessible treatments for patients worldwide.
Lonza
Lonza Group AG, headquartered in Switzerland, is a preeminent global Contract Development and Manufacturing Organization (CDMO) and a leading player in the human microbiome manufacturing services market. Lonza specializes in the production of microbial and Live Biotherapeutic Products (LBPs), which are the foundation of microbiome-based therapies. The company offers a comprehensive suite of end-to-end services crucial for translating microbiome research into commercial products. These services span from early-stage strain development and optimization to large-scale, Good Manufacturing Practice (GMP) compliant fermentation, downstream processing, and final fill-finish operations. Lonza has made significant strategic investments to expand its manufacturing capacity, incorporating advanced bioreactors, automated processing technologies, and dedicated LBP suites across its global network. Its strong expertise in navigating complex regulatory landscapes and its proven track record in collaborating with both emerging biotechs and established biopharma companies make it a preferred partner. Lonza’s role is critical in providing the necessary technological backbone and scalable capacity to accelerate the development, clinical supply, and eventual commercialization of the next generation of microbiome therapeutics, positioning it at the forefront of the industry’s infrastructure.
Chr. Hansen Holding A/S
Chr. Hansen Holding A/S, a global bioscience company, is recognized as a powerhouse in the development and supply of probiotic and microbiome solutions, primarily serving the food, beverage, and dietary supplement sectors. Leveraging deep expertise in microbial strains, fermentation, and bio-protection, the company translates advanced microbiome science into functional, evidence-based ingredients. Chr. Hansen maintains a robust, proprietary collection of over 40,000 microbial strains and continuously invests heavily in clinical research to validate the efficacy and safety of its probiotic strains for human health applications, including gut health and immunity. Its products, based on patented strains like *Lactobacillus* and *Bifidobacterium*, are integrated into thousands of consumer products worldwide. The company’s commitment to scientific rigor and state-of-the-art production capabilities allows it to deliver highly stable, standardized, and commercially scalable ingredients. By focusing on consumer-centric, natural solutions, Chr. Hansen is instrumental in driving the widespread adoption of microbiome-modulating products in the consumer health and nutrition markets globally.
Vedanta Biosciences
Vedanta Biosciences, Inc. is a clinical-stage company based in the U.S. that is a key innovator in the human microbiome therapeutic space. The company’s differentiated approach centers on developing a new class of oral medicines composed of defined bacterial consortia, carefully curated to restore microbial balance in diseased patients. Unlike therapeutics derived from human donor material, Vedanta utilizes a proprietary platform for the discovery, design, and cGMP manufacturing of its Live Biotherapeutic Products (LBPs) using pure, clonal bacterial strains from its extensive library. This donor-independent method ensures consistent composition, scalability, and high levels of control, addressing major manufacturing challenges in the field. Vedanta’s pipeline targets a range of therapeutic indications, including infectious diseases like C. difficile infection, inflammatory bowel disease (IBD), and various autoimmune conditions. By employing a science-driven process to select and combine non-pathogenic, commensal bacterial strains, Vedanta is well-positioned as a leader in developing highly characterized, safe, and effective precision medicines that modulate the microbiome for therapeutic benefit.
International Flavors & Fragrances Inc. (IFF)
International Flavors & Fragrances Inc. (IFF) is a global leader that plays a significant role in the human microbiome market by merging its deep expertise in nutrition, biosciences, and specialty ingredients. IFF develops and supplies next-generation probiotic, prebiotic, and postbiotic solutions to manufacturers in the food, beverage, and nutraceutical industries. The company excels at translating cutting-edge microbiome research into functional ingredients that are tailored for improving gut health and overall wellness. Leveraging advanced bioengineering and fermentation technologies, IFF creates highly effective microbial strains and bioactives. Its strategic acquisition activity and strong commitment to technology integration strengthen its position as a major innovator. IFF’s business model centers on acting as a preferred partner for health-focused brands worldwide, providing them with scientifically validated, scalable ingredients that enable the rapid development and commercialization of new microbiome-driven products, thereby profoundly influencing the consumer health segment of the market.
4D pharma plc
4D pharma plc, a UK-based biopharma company, is recognized as a pioneer in harnessing bacteria as a revolutionary new class of medicines known as Live Biotherapeutics (LBP). The company’s platform, MicroRx, is designed to identify and isolate single-strain, non-pathogenic bacteria from the human gut microbiome that have specific therapeutic effects. 4D pharma’s extensive pipeline focuses on diverse therapeutic indications, including oncology, metabolic disorders, and inflammatory conditions such as Irritable Bowel Syndrome (IBS) and Crohn’s disease. Its core innovation is the development of single-strain LBPs, which can be manufactured under pharmaceutical cGMP conditions to ensure consistency and quality. This innovative strategy focuses on moving beyond traditional probiotic mixtures to develop precision medicines that modulate the human immune system and metabolic pathways. The company’s innovative “push-and-pull” strategy in clinical trial phases and focus on a novel class of drugs position it as a key driver of the microbiome-targeting therapies sector.
Enterome
Enterome is a clinical-stage biopharmaceutical company based in France that is at the forefront of developing a novel generation of therapeutics, diagnostics, and nutritional products based on the human gut microbiome. The company leverages its proprietary metagenomic and functional analysis platforms to identify new drug targets and therapeutic candidates derived from the gut microbiota. Enterome’s focus areas include antibiotic research, immunotherapy, and inflammatory diseases. A notable advancement is its cutting-edge research in translational microbiome science, including the development of its OncoMimic platform. This platform uses bacterial peptides that mimic tumor antigens, designed to be used as novel cancer immunotherapy agents. By securing significant financing and progressing multiple candidates through the clinical pipeline, Enterome exemplifies a proactive approach to developing precision medicines. The company’s work is vital in expanding the application of microbiome science beyond gastroenterology and into high-impact fields like oncology, demonstrating the broad therapeutic potential of the human microbiome.
Evonik
Evonik Industries AG, a global specialty chemicals company based in Germany, is a leading provider of integrated Contract Development and Manufacturing Organization (CDMO) services within the human microbiome space. Evonik’s activities are centered on supporting the development and commercialization of live microbial therapeutics, probiotics, and postbiotics. The company’s expertise lies in bioprocess research and development, including advanced precision fermentation, microbial strain engineering, and innovative formulation technologies that ensure product stability and targeted delivery. With multiple Good Manufacturing Practice (GMP)-compliant facilities, Evonik has made strategic investments to expand its biomanufacturing platforms, thereby offering scalable production solutions for both clinical and commercial supply. By focusing on high-quality manufacturing and advanced delivery systems, Evonik plays a crucial role in enabling biopharma and nutraceutical companies to successfully bring complex, microbiome-based products to a global market, cementing its position as a key infrastructural partner in the industry.
Yakult Honsha Co., Ltd.
Yakult Honsha Co., Ltd. is a Japanese multinational company that is internationally recognized as one of the original pioneers in the commercial development of probiotic products. The company’s flagship product is the *Yakult* probiotic beverage, which contains its core, proprietary strain, *Lactobacillus casei* strain Shirota. Yakult’s contribution to the human microbiome market is rooted in over eight decades of dedicated scientific research and a commitment to preventive healthcare. Its research centers continually work to advance the clinical validation and understanding of the role of this specific *Lactobacillus casei* strain in gut health, immunity, and overall wellness. By focusing on consumer education and maintaining a massive global outreach, Yakult has been instrumental in shaping public awareness and broadening the worldwide acceptance and adoption of microbiome-based functional foods. Its long-standing scientific rigor and successful commercialization strategy ensure its enduring influence as a foundational company in the global consumer health microbiome sector.
Latest Market Research Report on Human Microbiome Download PDF Brochure Now